Regarding the investigation of the specific role of DCs in gliomas, an important breakthrough seems to be the recent finding of the role of fibrinogen-like protein 2 (FGL2) expressed in immune cells and in glioma cells, and this expression correlates with a worse clinical outcome. Here, FGL2 is linked to central nervous system cancer.